The changing epidemiology of hepatitis B in Greece

Eirini I. Rigopoulou, Nikolaos K. Gatselis, Konstantinos Galanis, Vasiliki Lygoura, Stella Gabeta, Kalliopi Zachou, George N. Dalekos

General University Hospital of Larissa, Greece

Abstract

Background The epidemiology of hepatitis B virus (HBV) infection has changed in recent years as a result of various factors. Our aim was to assess the epidemiological characteristics and the evolution of the HBV infection in a well-defined area of Greece.

Methods Prospectively collected data from 1910 consecutive patients (60.8% male, age: 50.1 years) with chronic hepatitis B (CHB) followed from 1999-2016 were analyzed.

Results Of the patients evaluated, 90.6% were of Greek and 8% of Albanian origin. Vertical/intrafamilial transmission during early childhood (56.8%) and traditional practices (17.2%) were the most common infection sources. Several areas with higher rates of CHB were identified. At first evaluation, 68.8% had chronic infection, 21.7% chronic hepatitis, 6.1% cirrhosis and 3.4% hepatocellular carcinoma (HCC). Comparison between 2 periods (1999-2010 and 2011-2016) revealed older age and longer disease duration at first presentation ($P<0.001$ for both) to be more common during 2011-2016, while patients of foreign nationality doubled during this period. There was a trend towards more advanced disease stage at first assessment during 2011-2016. Patients after 2011 had lower rates of virological and biochemical breakthrough ($P<0.001$ for both) during treatment with new antivirals. In addition, fewer patients progressed to cirrhosis ($P=0.02$) and HCC ($P=0.04$).

Conclusions CHB continues to be a major health problem in Central Greece, as highlighted by the preservation of high prevalence areas and a tendency towards an increase of chronic liver disease burden longitudinally. Our data highlight the need for scaling-up prevention and treatment strategies, especially in at-risk populations.

Keywords Hepatitis B, epidemiology, natural history, cirrhosis, hepatocellular carcinoma

Ann Gastroenterol 2021; 34 (2): 1-7

Introduction

Reports during the preceding decades have highlighted a decline in the worldwide prevalence of hepatitis B virus (HBV)

infection in many parts of the world [1]. Associated factors are the general improvement in socioeconomic status, the implementation of universal vaccination against HBV in high-prevalence countries and successful antiviral treatment [1]. However, migration waves during the last 15 years from high-medium to low endemicity countries have contributed towards substantial changes in HBV epidemiology in recent years [2].

HBV prevalence, as assessed by the presence of hepatitis B surface antigen (HBsAg), is estimated to be 3.6%, though there is significant variation between low (<2%) and high (>8%) endemicity areas [3]. Still, HBV remains a significant public health problem with a high disease burden, as evidenced by a rise in HBV-related cirrhosis and/or hepatocellular carcinoma (HCC) between 1990 and 2013 [4].

Greece is nowadays classified as a low-endemicity country for HBV, based on an estimated prevalence of 1.74% (corrected 1.88%) [5]. However, estimation of HBV prevalence in Greece remains a difficult task, considering the vast differences between neighboring regions and between groups with diverse characteristics [6-11]. We have previously shown an HBV prevalence of 4.2% in the general population of Central Greece

Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Greece

Conflict of Interest: None

Correspondence to: George N. Dalekos, MD, PhD, Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Mezourlo, 41110 Larissa, Greece, e-mail: georgedalekos@gmail.com

Received 25 September 2020; accepted: 4 January 2021; published online 26 February 2021

This work was presented as an oral e-poster (no 0127) at the 18th European Congress of Internal Medicine, 29-31 August 2019, Lisbon, Portugal

DOI: <https://doi.org/10.20524/aog.2021.0614>

between 1999 and 2004, with cluster areas for HBV inside this region [12].

These data underscore the need to assess the epidemiology of HBV in large-scale studies, contributing towards highlighting the magnitude of the disease and assisting in developing specific prevention and control strategies, including infant vaccination, prevention of mother-to-child transmission, population-wide testing and treatment [13-15].

Accordingly, our aim was to study the epidemiological characteristics and progression of HBV infection in a large consecutive cohort of chronic HBV patients. We focused on identifying risk factors related to disease progression to cirrhosis, decompensation, HCC development and liver-related death. In addition, we wanted to draw attention to areas with high HBV prevalence and to temporal trends in the epidemiological disease characteristics spanning a period of 18 years in the region of Thessaly.

Patients and methods

Patients

We prospectively analyzed data from 1910 consecutive patients with chronic HBV infection followed at the Department of Medicine and Research Laboratory of Internal Medicine, General University Hospital of Larissa, during an 18-year period (1 January 1999 to 31 December 2016; mean follow up 7.3 ± 4.6 years). Patients with chronic infection and chronic hepatitis were followed every 12 and 6 months, respectively, with relevant laboratory and imaging tests, while patients with cirrhosis (with or without HCC) were evaluated more frequently, according to individual requirements (every 3-6 months). The compliance of the studied population, especially of patients with chronic hepatitis or cirrhosis, was substantially good, irrespective of patients' educational level (data not shown).

The diagnosis of HBV infection was based on established international criteria [16,17]. Specifically, patients were classified according to the new nomenclature into the following categories: HBV e antigen (HBeAg)-positive chronic HBV infection, HBeAg-positive chronic hepatitis B (CHB), HBeAg-negative chronic HBV infection and HBeAg-negative CHB [16,17]. All patients were also tested for antibodies against hepatitis D virus (HDV). All patients tested negative for antibodies against hepatitis C virus and human immunodeficiency virus. The diagnosis of HCC was based on well-established criteria [16,18].

Data on the following parameters was collected: demographic characteristics (sex, ethnicity, place of ancestry and place of residency, educational level), reasons for initial HBV testing, clinical characteristics of HBV infection including mode of clinical presentation (acute or chronic), phase in the natural history of HBV, presence of cirrhosis and/or HCC at presentation, mode of transmission and risk factors, daily alcohol consumption (mild: <20 g and <10 g; moderate: 20-60 g and 10-40 g; and severe: >60 g or >40 g, for men and women

respectively), patients' biometrics, duration of infection and follow up. Laboratory data, including biochemistry, platelets, international normalized ratio, α -fetoprotein, and HBV-DNA (real-time PCR -Cobas® TaqMan 48; cutoff values for detection: 6 IU/mL), were recorded at regular time points according to established protocols.

Liver biopsy and the results of liver elastography, used as a noninvasive method for assessment of liver fibrosis, were recorded during presentation or follow-up visits. Treatment with interferon- α (IFN- α), pegylated-IFN- α (Peg-IFN- α) and nucleos(t)ide analogs was documented, as well as the response to treatment with these agents (biochemical, virological, virological breakthrough) [16,17]. Imaging results (ultrasound, computer tomography, magnetic resonance) were also recorded.

The outcomes of HBV infection, including HBsAg clearance, development of cirrhosis, decompensation of liver disease in cirrhotic patients, development of HCC, liver transplantation, and liver-related or liver-unrelated deaths were also documented.

Thessaly, located in central Greece, is one of the 13 peripheries of the country, with an estimated population of 750,000 people (census 2011; 6.8% of the national population). Thessaly is divided into prefectures: the prefecture of Larissa (capital city: Larissa), Magnesia including Sporades islands (capital city: Volos), Trikala (capital city: Trikala), Karditsa (capital city: Karditsa). As reported previously, we also estimated the ratio of HBV-infected patients (either originating or residing) in each municipality by dividing the number of patients infected in the respective region by the total number of infected patients in the respective prefecture [12].

All subjects consented to participate in the study. The ethics committee of the General University Hospital of Larissa approved the study protocol (2258/21-3-2016).

Statistical analysis

Data were entered and analyzed using SPSS and Epi-Info 2002 software. Normally distributed values are expressed as mean $\pm$ standard deviation, while non-normally distributed data are given as median and interquartile range (IQR). Data were analyzed by Student's *t*-test, χ^2 test (two by two with Yate's correction), Fisher's exact test, Kaplan-Meier log-rank test, Cox regression analysis, binary logistic regression model, and multiple Cox regression model, where appropriate. Two-sided P-values <0.05 were considered as statistically significant.

Results

Demographic and clinical characteristics of HBV patients

The epidemiological, clinical and laboratory characteristics of 1910 patients with chronic HBV infection during their first assessment are presented in Table 1. The vast majority of

Table 1 Epidemiological, clinical and laboratory characteristics of 1910 patients with chronic hepatitis B at their first assessment

Characteristics	n (%) or average $\pm$ SD
Sex: M/F	1161 (60.8%)/749 (39.2%)
Age (years)	50.1 $\pm$ 15.8
Duration of infection (years)	42.2 $\pm$ 15.8
BMI (kg/m ²)	26.6 $\pm$ 3.4
Alcohol use	
Yes (moderate or severe)	622 (32.6%)
No (mild or no)	1288 (67.4%)
Source of infection	
Vertical - intrafamilial	1085 (56.8%)
Traditional folk remedies	328 (17.2%)
Iatrogenic (blood transfusion/ dental treatment)	133 (6.9%)
Sexual	57 (3%)
i.v. substance use	3 (0.2%)
Professional exposure	7 (0.4%)
Unknown	297 (15.5%)
Educational level	
Illiterate – elementary education	1101 (57.7%)
Secondary education	507 (26.5%)
Higher education	302 (15.8%)
Ethnicity	
Greece	1731 (90.6%)
Albania	153 (8%)
Eastern Europe or Russia	22 (1.1%)
Africa/Germany/Pakistan	4 (0.2%)
Mode of presentation/ diagnosis of HBV infection	
Presence of symptoms	107 (5.6%)
Acute hepatitis	23 (1.2%)
Symptoms of chronic hepatitis	84 (4.4%)
Asymptomatic	1803 (94.4%)
Clinical phase of HBV infection	
Chronic infection (inactive carriers)	1314 (68.8%)
Chronic hepatitis (no cirrhosis)	415 (21.7%)
Cirrhosis (compensated and decompensated stage)	116 (6.1%)
Hepatocellular carcinoma	65 (3.4%)*
HBeAg; pos/neg	31 (1.6%) / 1879 (98.4%)
HBV DNA (IU/mL)	2.629.644 $\pm$ 13.291.480
Anti-HDV; pos/neg	30 (1.6%) / 1880 (98.4%)
Grade of fibrosis at first liver biopsy (n=262)	
No/mild fibrosis (F0-F1)	112 (42.8%)
Moderate fibrosis (F2)	86 (32.8%)
Severe fibrosis (F3)	26 (9.9%)
Cirrhosis (F4)	38 (14.5%)
PLT (/mm ³)	212256 $\pm$ 54005
INR	1.05 $\pm$ 0.18
AST (U/L), (ULN: 40)	46 $\pm$ 138
ALT (U/L), (ULN: 40)	61 $\pm$ 182
γ GT (U/L), (ULN: 37)	31 $\pm$ 36
Albumin (g/dL), (ULN: 3.5 - 5.2)	4.4 $\pm$ 0.5
Bilirubin (mg/dL), (ULN: 1.1)	0.9 $\pm$ 0.9
AFP (ng/mL), (ULN: 10)	6.9 $\pm$ 108.4

*All patients diagnosed with HCC during their first assessment had cirrhosis

N, number of patients in each respective group; M, male; F, female; BMI, body mass index; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; HBV DNA, hepatitis B virus DNA; anti-HDV, antibodies against hepatitis D virus; PLT, platelets; INR, international normalized ratio; AST, aspartate aminotransferase; ULN, upper limit of normal; ALT, alanine aminotransferase; γ GT, gamma glutamyl-transferase; AFP, alpha fetoprotein

patients (n=1803; 94.4%) were asymptomatic at presentation or initial assessment, and HBV diagnosis was established either during testing of first-degree relatives of HBV patients (n=691; 36.2%) or during blood donation (n=378; 19.8%).

Almost all patients (n=1897; 98.4%) were HBeAg-negative/anti-HBe-positive and 30 (1.5%) had HDV coinfection. At first assessment, 1314 patients (68.8%) had chronic infection, 415 (21.7%) had chronic hepatitis, 116 were cirrhotic—105 (5.5%) with compensated and 11 (0.6%) with decompensated cirrhosis—and 65 (3.4%) had HCC (all being cirrhotic). Patients' characteristics according to disease stage are shown in Table 2.

Non-cirrhotic patients with CHB compared to those with chronic infection were more frequently male ($P<0.001$), with higher alcohol consumption ($P<0.001$). Patients with cirrhosis and/or HCC compared to non-cirrhotic patients with CHB were more likely to be males ($P<0.001$), older ($P<0.001$), with longer disease duration ($P<0.001$), and reported higher alcohol consumption ($P=0.002$) (Table 2).

Distribution of HBV in the region of Thessaly

Considering that clusters of HBV exist in the region of Thessaly, we estimated the geographical distribution of HBV in different municipalities based on patients' origin and residence. Amongst the 1910 HBV-infected patients, 1632 (85.4%) originated from Thessaly, including 978 (59.9%) from the prefecture of Larissa, 269 (16.5%) from Karditsa, 247 (15.1%) from Trikala, and 138 (8.5%) from Magnesia.

After excluding the capital cities of Larissa, Karditsa, Trikala and Volos, we identified municipalities with a high HBV ratio. Municipalities with a high ratio of HBV patients according to their origin were the municipalities of Sofades

(15.2%) and Palama (4.1%) in the prefecture of Karditsa, the municipality of Kalampaka (14.6%) in the prefecture of Trikala, the municipalities of Tyrnavos (7.6%), Sarantaporo (7%), and Elassona (6.4%) in the prefecture of Larissa, and the municipality of Nea Ionia (4.4%) in the prefecture of Magnesia. Similarly, high HBV rates were recorded in people residing in these municipalities (data not shown).

Temporal trends in epidemiological and clinical characteristics

To assess whether changes in patients' epidemiological and clinical characteristics during their first assessment might have occurred over time, we divided the study into 2 periods: the first spanning 1999-2010 and the second 2011-2016. Patients evaluated for the first time during 2011-2016 (n=309) were older (55.1 ± 16.1 vs. 49.2 ± 15.6 years; $P<0.001$) and had longer disease duration (47 ± 16.5 vs. 41.3 ± 15.6 years; $P<0.001$) compared to patients from the period 1999-2010 (n=1601). During 2011-2016, patients with foreign nationality were more likely to have attended our department for the first time (16% vs. 8%; $P<0.001$). In addition, during the 2011-2016 period patients tended to have a more advanced disease stage (12.3% vs. 8.9%; $P=0.085$). There were no differences in terms of sex, history of alcohol consumption, educational level, HBeAg seropositivity and laboratory parameters between the 2 periods.

Treatment of HBV infection and response to treatment

During the whole study period, 529 of 596 (88.8%) patients with CHB received treatment with antivirals: IFN- α , Peg-

Table 2 Characteristics of HBV patients according to the stage of chronic HBV infection

Characteristics	Chronic infection (n=1314)	Chronic hepatitis non-cirrhotic (n=415)	Cirrhosis/ HCC (n=181)	P-value*	P-value†
Sex					
Male	732 (55.7%)	276 (66.5%)	153 (84.5%)	<0.001	<0.001
Female	582 (44.3%)	139 (33.5%)	28 (15.5%)		
Age (years)	48.5 $\pm$ 15.9	50.1 $\pm$ 15.5	61.7 $\pm$ 10.9	0.189	<0.001
Duration of infection (years)	41.0 $\pm$ 15.2	41.4 $\pm$ 16.5	53.4 $\pm$ 15.1	1.000	<0.001
Alcohol					
Yes	357 (27.2%)	157 (37.8%)	108 (59.7%)	<0.001	0.002
No	957 (72.8%)	258 (62.2%)	73 (40.3%)		
Educational level					
Illiterate/elementary	725 (55.2%)	236 (56.9%)	140 (77.3%)	0.267	<0.001
Secondary education	376 (28.6%)	103 (24.8%)	28 (15.5%)		
Higher education	213 (16.2%)	76 (18.3%)	13 (7.2%)		
Ethnicity					
Greek	1177 (89.6%)	379 (91.3%)	175 (96.7%)	0.346	0.029
Other	137 (10.4%)	36 (8.7%)	6 (3.3%)		

n=number of patients in each respective group. *comparison between patients with chronic infection (n=1314) and non-cirrhotic patients with chronic hepatitis (n=415). †comparison between non-cirrhotic patients with chronic hepatitis (n=415) and patients with cirrhosis and/or hepatocellular carcinoma (n=181)

HBV, hepatitis B virus; HCC, hepatocellular carcinoma

IFN- α , nucleos(t)ide analogs, or combination. Sixty-seven patients were not treated because of bad compliance, insurance issues, or as a result of personal decision.

Treatment with IFN- α or Peg-IFN- α was prescribed in 138 patients and response to treatment was reported in 31 (22.5%). Five hundred sixteen patients received nucleos(t)ide analogs. During follow up, 214 of 529 patients who received some kind of treatment (40.5%) had at least one episode of viral breakthrough and 204 (38.6%) had at least one episode of biochemical breakthrough. During the last visit, 519 patients (98.1%) had demonstrated a virological response to treatment.

Outcome of HBV patients

HBsAg loss occurred in 161 (8.4%) patients. The cumulative probabilities of HBsAg loss at 5-, 10- and 15-year follow up were 3.7%, 9.6% and 20.4%, respectively. HBsAg loss was not associated with any demographic or laboratory data, including HBV-DNA levels and also IFN- α -based treatment.

After a total follow up of 6.9 ± 4.3 years, none of the 1314 patients with chronic HBV infection progressed to CHB or had any liver-related events and were excluded from further analysis. The remaining 596 patients with CHB (with or without cirrhosis/HCC) were under follow up for 8.3 ± 5.1 years and were further analyzed in terms of outcome and possible prognostic parameters. Of the 415 non-cirrhotic patients, 51 (12.3%) developed cirrhosis, virological breakthrough during treatment being the only prognostic factor ($P=0.004$). The cumulative incidences of cirrhosis in the 1st, 5th, 10th and 15th years were 0.2%, 8.3%, 15.3% and 17.5%, respectively.

Of the 156 patients with cirrhosis (105 at initial visit and 51 during follow up), 34 patients (21.8%) developed symptoms related to decompensated liver disease, low albumin levels ($P=0.01$) and high alcohol consumption ($P=0.05$) being independent prognostic factors. The cumulative incidences of decompensation in the 1st, 5th, 10th and 15th years were 3.2%, 12.8%, 24.6% and 28.2%, respectively. During follow up, HCC was identified in 64 of the 531 (12.1%) patients with CHB. Of these, 41 were cirrhotic from their first evaluation, 23 patients developed cirrhosis during follow up and 11 patients were non-cirrhotic at HCC diagnosis. The cumulative incidences of HCC were 1.1%, 7.7%, 13.8% and 15.9% in the 1st, 5th, 10th and 15th years, respectively. The presence of cirrhosis ($P<0.001$) and virologic breakthrough during treatment ($P=0.05$) were independent negative predictive factors for HCC development.

Liver-related death occurred in 47 of the 531 (8.9%) patients who had CHB with or without cirrhosis at baseline. The cumulative incidences of liver-related death in the 1st, 5th, 10th and 15th years were 1.1%, 5.8%, 9.9% and 11.4%, respectively. On multivariate analysis, cirrhosis ($P<0.001$), disease duration ($P=0.03$) and low levels of albumin ($P=0.001$) were associated with liver-related death.

Patients who started follow up from 2011 and onwards had lower rates of virologic breakthrough (9.5 vs. 45.5%; $P<0.001$) and biochemical relapse during treatment (9.5 vs. 43.4%; $P<0.001$) compared to those first evaluated and treated before

2011. In addition, fewer patients progressed to cirrhosis (1.8% vs. 14%; $P=0.02$) and HCC (5.1% vs. 13.2%; $P=0.04$). In contrast, there were no significant differences in decompensation rates of cirrhotic patients or liver-related death.

We also performed a sub-analysis of 255 patients with CHB under treatment with tenofovir or entecavir (mean follow up: 6.2 ± 2.4 years). Patients with decompensated cirrhosis or HCC at the time of treatment initiation were excluded. HCC developed in 18 (7.1%) patients during follow up (mean time: 4.7 ± 1.9 years), increased age ($P<0.001$), and alcohol consumption ($P=0.01$) being independent prognostic factors. The cumulative incidences of HCC development at the 2nd, 3rd, 5th, 7th and 10th years after initiation of tenofovir or entecavir were 0.4%, 2.1%, 4.4%, 9.1%, and 10.2%, respectively.

Discussion

Our study, being one of the largest conducted in Greece so far, delivers important information regarding the epidemiological and clinical characteristics of HBV infection, in conjunction with their temporal changes, in a large cohort of HBV patients from Central Greece. We provide sufficient evidence to suggest that CHB continues to be a major public health problem in the wider region of Central Greece, while areas of high prevalence are still preserved. Another asset of our study is the homogeneity of our HBV cohort in terms of virus and host characteristics, considering that the great majority were Caucasians, originating and residing in the region of Thessaly.

Even though Greece is nowadays considered a country of low endemicity, our current data confirm and further extend those from our previous study, indicating that Thessaly remains a region with clusters of HBV infection [12]. Clusters of HBV pose a significant public health problem, as they maintain the virus transmission chain.

As previously reported, the transmission of HBV has been largely attributed to the intrafamilial mode, considering that two thirds of the population contracted the virus either through vertical transmission, or via intrafamilial modes [12]. Overcrowded living conditions in rural areas in Greece, where the majority of HBV clusters were identified, have been previously implicated as a risk factor for intrafamilial transmission [19]. Intrafamilial transmission of HBV occurs during early life, when most patients are asymptomatic during acute infection and remain asymptomatic thereafter. In fact, only 5% of our HBV population sought medical advice because of the presence of symptoms, while the vast majority were assessed during testing of first-degree relatives of HBV patients, volunteer blood donation, or during evaluation of asymptomatic transaminasemia and hospitalization. The mean duration of HBV infection up to diagnosis was 42 years in our population. As most of our patients were ignorant of their HBV status (data not shown), they represent a silent reservoir of the virus that could have maintained HBV circulation in the community for many years. The fact that universal vaccination was implemented in Greece in 1998 for infants and adolescents suggests that a significant part of Thessaly's population has been vulnerable to HBV for a long period.

In agreement with other studies, alcohol consumption was high in our cohort and was associated with advanced disease stage and progression of liver disease during follow up towards development of complications of cirrhosis and HCC [20-22]. As existing data have highlighted the synergistic role of alcohol and HBV in HCC development, public awareness as well as education of patients with chronic liver disease about the detrimental effects of alcohol is mandatory [20-22]. The long follow-up period, spanning almost 2 decades, was one of the strengths of our study, allowing us also to highlight temporal changes related to the study population and patients' characteristics associated with HBV infection.

The doubling of the number of non-Greek HBV patients during the second study period is in line with the acceleration of immigration waves from countries of higher HBV endemicity. This has been previously highlighted in different regions of Greece. In the Epirus region, 22.2% of Albanian migrants had serological evidence of CHB, which declined to 11.7% in young Albanian migrants in 2010 [23,24]. In the metropolitan area of Athens, the prevalence of HBV in migrants was 15.4% compared to 0.83% in the general population, while in the north-east region of Greece HBsAg prevalence was 25% in former USSR migrants and 12.3% in a Muslim population residing in the area [7,25]. This underscores the need for prioritizing systematic screening and scaling up of care services in at-risk populations, such as migrants from moderate- or high-endemicity countries [26].

Owing to the infrastructure of the health system in Greece, our center acts not only as a tertiary but also as a primary and secondary health center for the region of Thessaly [12,27,28]. This indicates that the volume of patients being evaluated in everyday clinical practice is significant and encompasses a variety of liver diseases. Still, we need to acknowledge that the burden of HBV infection in the region of Thessaly is underestimated in this analysis, as specific populations, including migrants arriving in Greece after 2016 and living mainly in hotspots, are not included herein. Studies from Canada have demonstrated that immigrants and refugees from East Asia have a higher possibility of dying from liver disease or developing HCC compared to the general population, contributing significantly towards a higher burden of chronic liver disease in these countries [2].

The Global Burden of Disease Study has shown that deaths due to cirrhosis with or without HCC have risen by 33% from 1990 to 2013 in CHB patients [4]. Analogously, the number of patients in our cohort who were cirrhotic or had HCC at first assessment tended to increase during the second study period, even though the percentage of patients with chronic hepatitis remained stable. From our data in a large region of Greece, we could extrapolate that HBV infection remains a major cause of disability and mortality in Greece, suggesting that there is a need for improvement of public health measures to recognize and treat the disease.

The advent of more potent antiviral treatments for CHB patients during the last decade has halted disease progression and further improved patients' survival, with a significant decline in HCC development [29-37]. Accordingly, our

analysis revealed temporal changes in response to HBV treatment, as demonstrated by an 80% reduction in virological and biochemical breakthrough episodes from 2011 and onwards compared to those reported before. Hence, more effective treatment with newer antivirals was associated with a significant decline in cirrhosis progression and HCC development.

In conclusion, CHB continues to be a major public health problem in Greece, and in particular in the wider region of Central Greece, while areas with high prevalence are still preserved. The burden of chronic liver disease tended to rise longitudinally, as attested by the increased number of patients diagnosed with advanced disease stages over time, with high alcohol consumption being an independent prognostic factor in our cohort. There was an improvement in the natural history of HBV infection over time, associated with the use of newer and more potent antiviral drugs. Our data highlight the need for scaling-up prevention and early detection strategies in our region with an emphasis on at-risk populations and implementation of treatment where appropriate.

Summary Box

What is already known:

- The epidemiology of hepatitis B virus (HBV) infection has changed worldwide lately as a result of various factors
- However, chronic hepatitis B continues to be a major public health problem in Greece
- Epidemiological characteristics and the evolution of HBV infection after long-term follow up in large number of patients in well-characterized areas of Greece are lacking

What the new findings are:

- As in other countries, there has been an improvement in the natural history of HBV infection in our region, associated with the use of the newer and more potent antiviral drugs
- However, during a follow up of 18 years in a large cohort of HBV patients (n=1910), the burden of chronic liver disease tended to rise longitudinally, as attested by the increased number of patients diagnosed with an advanced disease stage over time

References

1. Ott JJ, Horn J, Krause G, Mikolajczyk RT. Time trends of chronic HBV infection over prior decades - A global analysis. *J Hepatol* 2017;**66**:48-54.
2. Sharma S, Carballo M, Feld JJ, Janssen HL. Immigration and viral hepatitis. *J Hepatol* 2015;**63**:515-522.
3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations

- of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015;**386**:1546-1555.
4. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet* 2016;**388**:1081-1088.
 5. Touloumi G, Karakosta A, Sypsa V, et al; Hprolipsis Study Group. Design and development of a viral hepatitis and HIV infection screening program (Hprolipsis) for the general, Greek Roma, and migrant populations of Greece: protocol for three cross-sectional health examination surveys. *JMIR Res Protoc* 2020;**9**:e13578.
 6. Dalekos GN, Zervou E, Merkouroupoulos MH, Tsianos EV. Prevalence of hepatitis B and C viruses infection in chronic alcoholics with or without liver disease in Ioannina, Greece: low incidence of HCV infection. *Eur J Epidemiol* 1996;**12**:21-25.
 7. Kyriakis KP, Foudoulaki LE, Papoulia EI, Sofroniadou KE. Seroprevalence of hepatitis B surface antigen (HBsAg) among first-time and sporadic blood donors in Greece: 1991-1996. *Transfus Med* 2000;**10**:175-180.
 8. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. *Transfusion* 2001;**41**:652-658.
 9. Zacharakis GH, Koskinas J, Kotsiou S, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). *J Med Virol* 2005;**77**:173-179.
 10. Michos A, Terzidis A, Kalampoki V, Pantelakis K, Spanos T, Petridou ET. Seroprevalence and risk factors for hepatitis A, B, and C among Roma and non-Roma children in a deprived area of Athens, Greece. *J Med Virol* 2008;**80**:791-797.
 11. Papadakis G, Okoba NA, Nicolaou C, et al; Doctors of the World – Greece. Serologic markers for HBV, HCV and HIV in immigrants visiting the Athens' polyclinic of 'Doctors of the World - Greece'. *Public Health* 2013;**127**:1045-1047.
 12. Stefanos A, Gatselis N, Zachou K, Rigopoulou E, Hadjichristodoulou C, Dalekos GN. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. *Eur J Intern Med* 2009;**20**:35-43.
 13. Papamichail D, Petraki I, Arkoudis C, et al. Low vaccination coverage of Greek Roma children amid economic crisis: national survey using stratified cluster sampling. *Eur J Public Health* 2017;**27**:318-324.
 14. Nayagam S, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. *Lancet Infect Dis* 2016;**16**:1399-1408.
 15. Touloumi G, Karakosta A, Kaskafetou S, et al; Hprolipsis study group. Treatment cascade of hepatitis B and C in general, migrant and Roma populations. *J Hepatology* 2017;**66**(Suppl 1):S71-S72.
 16. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017;**67**:370-398.
 17. Dalekos GN, Goulis I, Manolakopoulos S, Papaevangelou V, Papatheodoridis GV, on behalf of the viral hepatitis scientific committee of the National Public Health Organization of Greece. Clinical practice guidelines on the management of hepatitis B virus infection. Available from: <https://eody.gov.gr/wp-content/uploads/2019/01/Odigies-HBV-2017-final.pdf> [Accessed 16 February 2021].
 18. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018;**69**:182-236.
 19. Zervou EK, Gatselis NK, Xanthi E, Ziciadis K, Georgiadou SP, Dalekos GN. Intrafamilial spread of hepatitis B virus infection in Greece. *Eur J Gastroenterol Hepatol* 2005;**17**:911-915.
 20. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. *Hepatology* 2002;**36**:1206-1213.
 21. Shiomi S, Kuroki T, Minamitani S, et al. Effect of drinking on the outcome of cirrhosis in patients with hepatitis B or C. *J Gastroenterol Hepatol* 1992;**7**:274-276.
 22. Larkin J, Clayton MM, Liu J, Feitelson MA. Chronic ethanol consumption stimulates hepatitis B virus gene expression and replication in transgenic mice. *Hepatology* 2001;**34**:792-797.
 23. Dalekos GN, Zervou E, Karabini F, Tsianos EV. Prevalence of viral markers among refugees from southern Albania: increased incidence of infection with hepatitis A, B and D viruses. *Eur J Gastroenterol Hepatol* 1995;**7**:553-558.
 24. Milonis C. Serological markers of Hepatitis B and C among juvenile immigrants from Albania settled in Greece. *Eur J Gen Pract* 2010;**16**:236-240.
 25. Papoutselis KM, Kotsiou SS, Zacharakis G, et al. Epidemiology of hepatitis B and C viral infections in minorities of Thrace: Immigrants from the former USSR and muslim religious minority in relation to the general population of Thrace. *J Hepatol* 2001;**34**(Suppl 1):175-176.
 26. Cooke GS, Andrieux-Meyer I, Applegate TL, et al; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. *Lancet Gastroenterol Hepatol* 2019;**4**:135-184.
 27. Gatselis NK, Rigopoulou E, Stefanos A, Kardasi M, Dalekos GN. Risk factors associated with HCV infection in semi-rural areas of central Greece. *Eur J Intern Med* 2007;**18**:48-55.
 28. Gatselis NK, Zachou K, Lygoura V, et al. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. *Eur J Intern Med* 2017;**42**:81-88.
 29. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. *Hepatology* 2010;**52**:886-893.
 30. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet. Greece cohort. *J Viral Hepat* 2015;**22**:120-127.
 31. Vourli G, Papatheodoridis G, Raptopoulou M, et al. Association of antiviral therapy with reduced disease progression in chronic hepatitis B patients: Results from a nation-wide cohort study. *Hippokratia* 2016;**20**:214-221.
 32. Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. *Hepatology* 2016;**63**:284-306.
 33. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. *J Hepatol* 2015;**62**:363-370.
 34. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *J Hepatol* 2016;**64**:800-806.
 35. Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. *Hepatology* 2017;**66**:1444-1453.
 36. Papatheodoridis GV, Sypsa V, Dalekos G, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. *J Hepatol* 2018;**68**:1129-1136.
 37. Papatheodoridis GV, Sypsa V, Dalekos GN, et al. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. *J Hepatol* 2020;**72**:1088-1096.